[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
EXPLORE, a new service to identify and validate therapeutic targets, primarily cancer treatments – an area of expertise and excellence at Oncodesign to discover and investigate preclinical proofs of concept involving a wide variety of different approaches and anti-cancer mechanisms of action.
EXPLORE, is the combination of our OncoSNIPER platform and a tailored and well established experimental validation process organized by indication and target.
Taking inspiration from approaches based in bioinformatics and artificial intelligence to analyze clinical, genome and medical imaging data collected as part of transversal patient monitoring, our ambition is to be able to stratify patient populations in order to understand the underlying pathological mechanisms and identify new therapeutic targets in oncology.
EXPLORE also puts Oncodesign’s more than 25 years’ of experience in implementing experimental models to good use in order to validate the targets identified by OncoSNIPER.
Thanks to our investment and development in Artificial Intelligence within our IA Business Unit as well as our focus on experimentation, the EXPLORE solution is designed to support you:
Solo, offers from our innovative technical platforms
INPACT: an integrated service in preclinical pharmacology